Consistent with studies in rats which showed that GLP-1 analogs may protect the heart against ischemia/reperfusion injury by improving cardiac energetics and function (Bao et al., 2011), observations from a pilot clinical study suggest that therapies aimed to increase GLP-1 action may counteract oxidative stress, protect from cardiac remodeling, and prevent cardiovascular events in patients with T2DM associated with low circulating levels of GLP-1 (Ravassa et al., 2015). This evidence concerns the gene GCG and type 2 diabetes mellitus.